Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency
| Autor: | Shigeki Yamada, Kazuo Takahashi, Tomohiro Mizuno, Masakazu Hatano, Koki Kato, Takenao Koseki, Naotake Tsuboi, Yoshimasa Ito |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Vonoprazan Rabeprazole Lansoprazole Ipilimumab Pembrolizumab Gastroenterology General Biochemistry Genetics and Molecular Biology Esomeprazole Atezolizumab Internal medicine medicine Humans Immune Checkpoint Inhibitors Pharmacology Nephritis business.industry Proton Pump Inhibitors Nivolumab business Omeprazole Research Article medicine.drug |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.12570 |
| Popis: | Background/Aim: Concomitant proton pump inhibitor (PPI) and immune checkpoint inhibitor (ICPI) were determined as risk factors of acute kidney injury. To identify the type of PPI associated with ICPI-induced nephritis, we used the Japanese Adverse Drug Event Report database. Patients and Methods: ICPIs (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, and avelumab) and PPIs (esomeprazole, omeprazole, vonoprazan, rabeprazole, and lansoprazole) were selected as suspected nephritis-inducing drugs. Results: The cases of concomitant use of atezolizumab and rabeprazole, ipilimumab and omeprazole, ipilimumab and lansoprazole, nivolumab and esomeprazole, nivolumab and omeprazole, nivolumab and rabeprazole, nivolumab and lansoprazole, pembrolizumab and esomeprazole, as well as pembrolizumab and lansoprazole had a significantly higher reported odds ratio than monotherapy cases. Conclusion: Male patients or patients using ICPIs and PPIs (excluded vonoprazan) concomitantly should be monitored for renal function after chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|